These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 35042142)

  • 1. More than saving lives: Qualitative findings of the UNODC/WHO Stop Overdose Safely (S-O-S) project.
    Walker S; Dietze P; Poznyak V; Campello G; Kashino W; Dzhonbekov D; Kiriazova T; Nikitin D; Terlikbayeva A; Nevendorff L; Busse A; Krupchanka D
    Int J Drug Policy; 2022 Feb; 100():103482. PubMed ID: 35042142
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An observational prospective cohort study of naloxone use at witnessed overdoses, Kazakhstan, Kyrgyzstan, Tajikistan, Ukraine.
    Dietze P; Gerra G; Poznyak V; Campello G; Kashino W; Dzhonbekov D; Kiriazova T; Nikitin D; Terlikbayeva A; Krupchanka D; Busse A
    Bull World Health Organ; 2022 Mar; 100(3):187-195. PubMed ID: 35261407
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A systematic review of the distribution of take-home naloxone in low- and middle-income countries and barriers to the implementation of take-home naloxone programs.
    Sajwani HS; Williams AV
    Harm Reduct J; 2022 Oct; 19(1):117. PubMed ID: 36266701
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Take-Home Naloxone and risk management from the perspective of people who survived an opioid overdose in Stockholm - An analysis informed by drug, set and setting.
    Holmén E; Hammarberg A; Kåberg M; Storbjörk J
    Int J Drug Policy; 2023 May; 115():104021. PubMed ID: 37011507
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Designing, implementing and evaluating the overdose response with take-home naloxone model of care: An evaluation of client outcomes and perspectives.
    Lintzeris N; Monds LA; Bravo M; Read P; Harrod ME; Gilliver R; Wood W; Nielsen S; Dietze PM; Lenton S; Shanahan M; Jauncey M; Jefferies M; Hazelwood S; Dunlop AJ; Greenaway M; Haber P; Ezard N; Malcom A
    Drug Alcohol Rev; 2020 Jan; 39(1):55-65. PubMed ID: 31774221
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is a randomised controlled trial of take home naloxone distributed in emergency settings likely to be feasible and acceptable? Findings from a UK qualitative study exploring perspectives of people who use opioids and emergency services staff.
    Sampson FC; Hughes J; Long J; Buykx P; Goodacre SW; Snooks H; Edwards A; Evans B; Jones J; Moore C; Johnston S
    BMC Emerg Med; 2024 Apr; 24(1):75. PubMed ID: 38679713
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Addiction stigma and the production of impediments to take-home naloxone uptake.
    Fomiatti R; Farrugia A; Fraser S; Dwyer R; Neale J; Strang J
    Health (London); 2022 Mar; 26(2):139-161. PubMed ID: 32529843
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A qualitative study of repeat naloxone administrations during opioid overdose intervention by people who use opioids in New York City.
    Parkin S; Neale J; Brown C; Jones JD; Brandt L; Castillo F; Campbell ANC; Strang J; Comer SD
    Int J Drug Policy; 2021 Jan; 87():102968. PubMed ID: 33096365
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Injection Drug Use Frequency Before and After Take-Home Naloxone Training.
    Colledge-Frisby S; Rathnayake K; Nielsen S; Stoove M; Maher L; Agius PA; Higgs P; Dietze P
    JAMA Netw Open; 2023 Aug; 6(8):e2327319. PubMed ID: 37540514
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A study protocol for a European, mixed methods, prospective, cohort study of the effectiveness of naloxone administration by community members, in reversing opioid overdose: NalPORS.
    Metrebian N; Carter B; Eide D; McDonald R; Neale J; Parkin S; Dascal T; Mackie C; Day E; Guterstam J; Horsburgh K; Kåberg M; Kelleher M; Smith J; Thiesen H; Strang J
    BMC Public Health; 2023 Aug; 23(1):1608. PubMed ID: 37612698
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acceptability of prison-based take-home naloxone programmes among a cohort of incarcerated men with a history of regular injecting drug use.
    Curtis M; Dietze P; Aitken C; Kirwan A; Kinner SA; Butler T; Stoové M
    Harm Reduct J; 2018 Sep; 15(1):48. PubMed ID: 30241532
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Twenty years of take-home naloxone for the prevention of overdose deaths from heroin and other opioids-Conception and maturation.
    McDonald R; Campbell ND; Strang J
    Drug Alcohol Depend; 2017 Sep; 178():176-187. PubMed ID: 28654870
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Take-home naloxone programs for suspected opioid overdose in community settings: a scoping umbrella review.
    Moustaqim-Barrette A; Dhillon D; Ng J; Sundvick K; Ali F; Elton-Marshall T; Leece P; Rittenbach K; Ferguson M; Buxton JA
    BMC Public Health; 2021 Mar; 21(1):597. PubMed ID: 33771150
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [First Aid Training for Drug Overdose in Opioid Addicts and Provision of Take-Home Naloxone on Release from Prison: Feasibility Study from the Bavarian Model Project].
    Wodarz-von Essen HJ; Wolstein J; Pogarell O; Wodarz N
    Gesundheitswesen; 2023 Jun; 85(6):568-572. PubMed ID: 36126950
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design details for overdose education and take-home naloxone kits: Codesign with family medicine, emergency department, addictions medicine and community.
    Sellen K; Goso N; Halleran L; Mulvale-Fletcher A; Sarmiento F; Ligabue F; Handford C; Klaiman M; Milos G; Wright A; Charles M; Sniderman R; Hunt R; Parsons JA; Leece P; Hopkins S; Shahin R; Jüni P; Morrison L; Campbell DM; Strike C; Orkin A;
    Health Expect; 2022 Oct; 25(5):2440-2452. PubMed ID: 35909312
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A rapid assessment of take-home naloxone provision during COVID-19 in Europe.
    McDonald R; Eide D; Abel-Ollo K; Barnsdale L; Carter B; Clausen T; Day E; Fonseca F; Holmén E; Horsburgh K; Kelleher M; Kåberg M; Ladenhauf M; McAuley A; Metrebian N; Neale J; Parkin S; Ratcliffe K; Rintoul C; Smith J; Stifanoviciute V; Torrens M; Thiesen H; Strang J
    Int J Drug Policy; 2022 Sep; 107():103787. PubMed ID: 35849935
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Take-Home Naloxone Kits: Attitudes and Likelihood-Of-Use Outcomes from a European Survey of Potential Overdose Witnesses.
    McDonald R; Breidahl S; Abel-Ollo K; Akhtar S; Clausen T; Day E; Kelleher M; McAuley A; Petersen H; Sefranek M; Thiesen H; Strang J
    Eur Addict Res; 2022; 28(3):220-225. PubMed ID: 35114666
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overdose and take-home naloxone in emergency settings: A pilot study examining feasibility of delivering brief interventions addressing overdose prevention with 'take-home naloxone' in emergency departments.
    Black E; Monds LA; Chan B; Brett J; Hutton JE; Acheson L; Penm J; Harding S; Strumpman D; Demirkol A; Lintzeris N
    Emerg Med Australas; 2022 Aug; 34(4):509-518. PubMed ID: 35021268
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Overdose Response with Take Home Naloxone (ORTHN) project: Evaluation of health worker training, attitudes and perceptions.
    Monds LA; Bravo M; Mills L; Malcolm A; Gilliver R; Wood W; Harrod ME; Read P; Nielsen S; Dietze PM; Lenton S; Bleeker AM; Lintzeris N
    Drug Alcohol Rev; 2022 Jul; 41(5):1085-1094. PubMed ID: 35442514
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Accessing Take-Home Naloxone in British Columbia and the role of community pharmacies: Results from the analysis of administrative data.
    Moustaqim-Barrette A; Papamihali K; Mamdani Z; Williams S; Buxton JA
    PLoS One; 2020; 15(9):e0238618. PubMed ID: 32915834
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.